Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Short-Term Debt issuances (2020 - 2022)

Guided Therapeutics (GTHP) has disclosed Short-Term Debt issuances for 3 consecutive years, with -$90000.0 as the latest value for Q1 2022.

  • Quarterly Short-Term Debt issuances rose 83.84% to -$90000.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was -$842000.0 through Mar 2022, changed N/A year-over-year, with the annual reading at -$1.5 million for FY2021, 33.33% down from the prior year.
  • Short-Term Debt issuances hit -$90000.0 in Q1 2022 for Guided Therapeutics, down from -$53000.0 in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of -$53000.0 in Q4 2021 to a low of -$557000.0 in Q1 2021.
  • Historically, Short-Term Debt issuances has averaged -$210500.0 across 3 years, with a median of -$116000.0 in 2020.
  • Biggest five-year swings in Short-Term Debt issuances: skyrocketed 62.68% in 2021 and later skyrocketed 83.84% in 2022.
  • Year by year, Short-Term Debt issuances stood at -$142000.0 in 2020, then surged by 62.68% to -$53000.0 in 2021, then plummeted by 69.81% to -$90000.0 in 2022.
  • Business Quant data shows Short-Term Debt issuances for GTHP at -$90000.0 in Q1 2022, -$53000.0 in Q4 2021, and -$557000.0 in Q1 2021.